Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 28.51
NAS:SRPT's Cash-to-Debt is ranked lower than
53% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. NAS:SRPT: 28.51 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:SRPT' s Cash-to-Debt Range Over the Past 10 Years
Min: 4.29  Med: No Debt Max: No Debt
Current: 28.51
Equity-to-Asset 0.84
NAS:SRPT's Equity-to-Asset is ranked higher than
65% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:SRPT: 0.84 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:SRPT' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.09  Med: 0.88 Max: 0.98
Current: 0.84
-0.09
0.98
Piotroski F-Score: 4
Altman Z-Score: 11.06
Beneish M-Score: 11.40
WACC vs ROIC
14.59%
-726.61%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -1131.61
NAS:SRPT's Operating Margin % is ranked lower than
89% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. NAS:SRPT: -1131.61 )
Ranked among companies with meaningful Operating Margin % only.
NAS:SRPT' s Operating Margin % Range Over the Past 10 Years
Min: -17572.55  Med: -215.28 Max: -71.16
Current: -1131.61
-17572.55
-71.16
Net Margin % -567.04
NAS:SRPT's Net Margin % is ranked lower than
90% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. NAS:SRPT: -567.04 )
Ranked among companies with meaningful Net Margin % only.
NAS:SRPT' s Net Margin % Range Over the Past 10 Years
Min: -17560.26  Med: -286.12 Max: -4.93
Current: -567.04
-17560.26
-4.93
ROE % -43.00
NAS:SRPT's ROE % is ranked lower than
82% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. NAS:SRPT: -43.00 )
Ranked among companies with meaningful ROE % only.
NAS:SRPT' s ROE % Range Over the Past 10 Years
Min: -309.2  Med: -100.95 Max: -16.44
Current: -43
-309.2
-16.44
ROA % -33.53
NAS:SRPT's ROA % is ranked lower than
82% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. NAS:SRPT: -33.53 )
Ranked among companies with meaningful ROA % only.
NAS:SRPT' s ROA % Range Over the Past 10 Years
Min: -93.53  Med: -64.53 Max: -4.62
Current: -33.53
-93.53
-4.62
ROC (Joel Greenblatt) % -652.61
NAS:SRPT's ROC (Joel Greenblatt) % is ranked lower than
58% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. NAS:SRPT: -652.61 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:SRPT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -978.9  Med: -575.45 Max: -309.3
Current: -652.61
-978.9
-309.3
3-Year Revenue Growth Rate -35.80
NAS:SRPT's 3-Year Revenue Growth Rate is ranked lower than
80% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. NAS:SRPT: -35.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:SRPT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -73.3  Med: 7.45 Max: 343.4
Current: -35.8
-73.3
343.4
3-Year EBITDA Growth Rate 26.80
NAS:SRPT's 3-Year EBITDA Growth Rate is ranked higher than
78% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. NAS:SRPT: 26.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:SRPT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -36.3  Med: 3.05 Max: 62.1
Current: 26.8
-36.3
62.1
3-Year EPS without NRI Growth Rate 18.40
NAS:SRPT's 3-Year EPS without NRI Growth Rate is ranked higher than
73% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. NAS:SRPT: 18.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:SRPT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -62.2  Med: 0.2 Max: 213.5
Current: 18.4
-62.2
213.5
GuruFocus has detected 3 Warning Signs with Sarepta Therapeutics Inc $NAS:SRPT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:SRPT's 30-Y Financials

Financials (Next Earnings Date: 2017-07-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

SRPT Guru Trades in Q2 2016

Steven Cohen 900,000 sh (unchged)
Steven Cohen 250,000 sh (unchged)
Steven Cohen 2,747,600 sh (-7.25%)
Columbia Wanger 641,932 sh (-42.68%)
» More
Q3 2016

SRPT Guru Trades in Q3 2016

Louis Moore Bacon 70,000 sh (New)
Paul Tudor Jones 215,933 sh (New)
Steven Cohen 3,284,287 sh (+19.53%)
Steven Cohen 250,000 sh (unchged)
First Eagle Investment 300 sh (unchged)
Columbia Wanger Sold Out
» More
Q4 2016

SRPT Guru Trades in Q4 2016

Jim Simons 49,078 sh (New)
First Eagle Investment 300 sh (unchged)
Steven Cohen 100,000 sh (unchged)
Paul Tudor Jones Sold Out
Steven Cohen 1,367,599 sh (-58.36%)
» More
Q1 2017

SRPT Guru Trades in Q1 2017

Paul Tudor Jones 80,929 sh (New)
John Paulson 78,101 sh (New)
Jim Simons 86,078 sh (+75.39%)
Louis Moore Bacon Sold Out
Steven Cohen 803,300 sh (-41.26%)
» More
» Details

Insider Trades

Latest Guru Trades with SRPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:AVXS, NAS:FGEN, OTCPK:MPSYY, NAS:TBPH, NAS:DBVT, NYSE:CBM, OTCPK:BVNRY, NAS:HALO, NAS:ONCE, NAS:PRTA, NAS:AAAP, NAS:PTLA, NAS:BPMC, NAS:LXRX, NYSE:AXON, NAS:BGNE, NAS:CLVS, NAS:AGIO, NAS:LGND, NAS:ARRY » details
Traded in other countries:AB3A.Germany,
Headquarter Location:USA
Sarepta Therapeutics Inc is a biotechnology company. It uses proprietary RNA-targeted technology platforms for developing pharmaceutical products to address serious diseases.

Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.

Top Ranked Articles about Sarepta Therapeutics Inc

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Announces First Quarter 2017 Financial Results and Recent Corporate Developments
Sarepta Therapeutics to Announce First Quarter 2017 Financial Results and Recent Corporate Developments on April 27, 2017
Sarepta Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Announces Appointment of Catherine Stehman-Breen, M.D., M.S. as Chief Medical Officer
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Announces Addition of Kenneth Fischbeck, M.D. and Matthew Wood M.D., Ph.D. to the Company’s Strategic and Scientific Advisory Board

CAMBRIDGE, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, today announced the addition of Kenneth Fischbeck, M.D., and Matthew Wood, M.D., Ph.D., to the Company’s Strategic and Scientific Advisory Board. Dr. Fischbeck and Dr. Wood join Dr. Beverly Davidson and Dr. Louis Kunkel, who were appointed to the board at the time of its formation in 2015.
“We are honored and excited to have Dr. Fischbeck and Dr. Wood join our advisory board,” said Edward Kaye, Sarepta’s chief executive officer. “Following the approval of our exon 51 skipping drug, EXONDYS 51™ (eteplirsen) Injection, our board members helped in guiding our strategy to move additional exon skipping therapies into later stage clinical development, rapidly advance our PPMO platform into the clinic, explore complimentary therapies to further improve the lives of patients with DMD, and expand our partnerships and research collaborations. The addition of Dr. Fischbeck and Dr. Wood adds to our board’s diversity of experience with Duchenne and neurological diseases and provides Sarepta with unique counsel for our research and development efforts.” Kenneth Fischbeck, M.D., received A.B. and A.M. degrees from Harvard University and a M.D. degree from Johns Hopkins. After a medical internship at Case Western Reserve University and a neurology residency at the University of California in San Francisco, he did postdoctoral research on muscular dystrophy at the University of Pennsylvania. In 1982, he joined the faculty in the Neurology Department at the University of Pennsylvania Medical School. In 1998, he joined the National Institute of Neurological Disorders and Stroke (NINDS) as Chief of the Neurogenetics Branch. He received the Cotzias Award from the American Academy of Neurology and the Jacoby Award from the American Neurological Association, and he was elected to the Institute of Medicine. His research group is identifying the causes and studying the mechanisms of hereditary neurological and neuromuscular diseases with the goal of developing effective treatment for these disorders. Matthew Wood, M.D., Ph.D., is a Professor of Neuroscience and Deputy Head of the Medical Sciences Division at the University of Oxford and directs the Laboratory of RNA biology and Neuromuscular Disease. Dr. Wood is a leading pioneer in the field of oligonucleotide therapies and co-leads the International MDEX Consortium, a major international translational medicine collaboration to develop oligonucleotide treatments for DMD and related neuromuscular conditions, with Dr. Francesco Muntoni of University College London. Sarepta’s EXONDYS 51 was the first oligonucleotide worked on by this Consortium. Dr. Wood is an executive member of the global alliance TREAT-NMD. Dr. Wood serves as a Director of several organizations, including the Oxford MDUK Centre for Translational Neuromuscular Science, the University of Oxford’s technology transfer organization, Oxford University Innovation, and Evox Therapeutics, a company he founded based on his work with exosomes. He currently serves as the Deputy Head of the Medical Sciences Division of the University of Oxford, and holds a Director role on the Board of MedCity. About EXONDYS 51™ EXONDYS 51 uses Sarepta’s proprietary phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 51 of the dystrophin gene. EXONDYS 51 is designed to bind to exon 51 of dystrophin pre-mRNA, resulting in exclusion of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. Exon skipping is intended to allow for production of an internally truncated dystrophin protein. Data from clinical studies of EXONDYS 51 in a small number of DMD patients have demonstrated a consistent safety and tolerability profile. The pivotal trials were not designed to evaluate long-term safety and a clinical benefit of EXONDYS 51 has not been established. Important Safety Information Adverse reactions in DMD patients (N=8) treated with 30 or 50 mg/kg/week of EXONDYS 51 with incidence of at least 25% more than placebo (N=4) (Study 1) were: balance disorder (38%), vomiting (38%) and contact dermatitis (25%). The most common adverse reactions were balance disorder and vomiting. Because of the small numbers of patients, these represent crude frequencies that may not reflect the frequencies observed in practice. The 50 mg/kg once weekly dosing regimen of EXONDYS 51 is not recommended.

In the 88 patients who received ≥30 mg/kg/week of EXONDYS 51 for up to 208 weeks in clinical studies, the following events were reported in ≥10% of patients and occurred more frequently than on the same dose in Study 1: vomiting, contusion, excoriation, arthralgia, rash, catheter site pain, and upper respiratory tract infection.

There have been reports of transient erythema, facial flushing, and elevated temperature occurring on the day of EXONDYS 51 infusion. Please see the U.S. Full Prescribing Information for EXONDYS 51 (eteplirsen) at www.EXONDYS51.com. About Sarepta Therapeutics Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit us at www.sarepta.com. Forward-Looking Statements This press release contains statements that are forward-looking within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “may,” “intends,” “prepares,” “looks,” “potential,” “possible” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating to the potential benefits of Sarepta’s Strategic and Scientific Advisory Board (SSAB), including in guiding Sarepta’s strategy to move follow on exons into later stage trials, rapidly advance PPMO candidates into clinical studies, improve the lives of patients by exploring complimentary therapies, and expand collaborations; Sarepta’s ability to execute its strategy; and the potential benefits of adding Dr. Fischbeck and Dr. Wood to Sarepta’s SSAB, including providing Sarepta with unique counsel for its research and development efforts.  These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta’s control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: we may not be able to capitalize and benefit from having the SSAB or from each of its specific members; we may not be able to complete clinical trials required by the FDA for approval of our product candidates; the results of our ongoing research and development efforts and clinical trials for our product candidates may not be positive or consistent with prior results or demonstrate a safe treatment benefit; we may not be able to execute on our business strategy and plans, including successfully moving more follow on exons into later stage trials, rapidly advancing PPMO candidates into clinical studies, improving the lives of patients by exploring complimentary therapies, and expand collaborations, bringing EXONDYS 51 to markets outside the United States, bringing our other product candidates to market or be able to meet related expected or planned clinical development plans, regulatory milestones and timelines, for various reasons including possible limitations of Company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, and regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product candidates; and those risks identified under the heading “Risk Factors” in Sarepta’s most recent Annual Report on Form 10-K for the year ended December 31, 2016 and Sarepta’s most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review. Any of the foregoing risks could materially and adversely affect the Company’s business, results of operations and the trading price of Sarepta’s common stock. You should not place undue reliance on for-ward-looking statements. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except to the extent required by applicable law or SEC rules. Internet Posting of Information We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.  

Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
[email protected]
or
W2O Group
Brian Reid, 212-257-6725
[email protected]

Read more...
Sarepta Therapeutics Announces Presentations at the 2017 MDA Scientific Conference

CAMBRIDGE, Mass., March 17, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, today provided an update to investors that it will present data from eteplirsen studies at the MDA Scientific Conference in Arlington, Virginia on March 19-22. Sarepta is scheduled to give an oral, as well as poster presentation, on the cardiac function of eteplirsen-treated patients; a poster presentation on non-ambulatory patients; and a poster presentation on the pulmonary function of eteplirsen-treated patients.
Details of Sarepta’s presentations at the MDA Scientific Conference are as follows: Oral Presentation and Poster:
Title: Effects of Long-Term Treatment with Eteplirsen on Cardiac Function: Left Ventricular Ejection Fraction in Eteplirsen-Treated Patients vs Disease Natural History
Date and Time: Wednesday, March 22, 10:45-11:00am ET Posters:
Title: Effects of Long-Term Treatment with Eteplirsen on Cardiac Function: Left Ventricular Ejection Fraction in Eteplirsen-Treated Patients vs Disease Natural History Title: Long-Term Treatment with Eteplirsen in Non-ambulatory Patients: A Case Study in Identical Twins Title: Effects of Long-Term Treatment With Eteplirsen on Pulmonary Function in Patients With Duchenne Muscular Dystrophy: Findings of Two Phase 2 Clinical Trials About EXONDYS 51™ EXONDYS 51 uses Sarepta’s proprietary phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 51 of the dystrophin gene. EXONDYS 51 is designed to bind to exon 51 of dystrophin pre-mRNA, resulting in exclusion of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. Exon skipping is intended to allow for production of an internally truncated dystrophin protein. Data from clinical studies of EXONDYS 51 in a small number of DMD patients have demonstrated a consistent safety and tolerability profile. The pivotal trials were not designed to evaluate long-term safety and a clinical benefit of EXONDYS 51 has not been established. Important Safety Information Adverse reactions in DMD patients (N=8) treated with 30 or 50 mg/kg/week of EXONDYS 51 with incidence of at least 25% more than placebo (N=4) (Study 1) were: balance disorder (38%), vomiting (38%) and contact dermatitis (25%). The most common adverse reactions were balance disorder and vomiting. Because of the small numbers of patients, these represent crude frequencies that may not reflect the frequencies observed in practice. The 50 mg/kg once weekly dosing regimen of EXONDYS 51 is not recommended.
 In the 88 patients who received ≥30 mg/kg/week of EXONDYS 51 for up to 208 weeks in clinical studies, the following events were reported in ≥10% of patients and occurred more frequently than on the same dose in Study 1: vomiting, contusion, excoriation, arthralgia, rash, catheter site pain, and upper respiratory tract infection.
 There have been reports of transient erythema, facial flushing, and elevated temperature occurring on the day of EXONDYS 51 infusion. Please see the EXONDYS 51 (eteplirsen) U.S. Full Prescribing Information at www.EXONDYS51.com. About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates. For more information, please visit us at www.sarepta.com. Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
[email protected]
or
W2O Group
Brian Reid, 212-257-6725
[email protected]

Read more...
Sarepta Therapeutics to Present Company Overview at the Cowen and Company 37th Annual Health Care Conference

CAMBRIDGE, Mass., March 02, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial stage developer of innovative RNA-targeted therapeutics, today announced that it is scheduled to present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA on Wednesday, March 8 at 8:00 a.m. ET. Edward Kaye, Sarepta's chief executive officer, will be the presenter at the fireside chat. The presentation will be webcast live on the investor relations section of the Sarepta Therapeutics website at www.sarepta.com and will be archived under the events and presentations section following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary. About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit us at www.sarepta.com. Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our web site at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.


Sarepta Therapeutics, Inc.
Media and Investors:
Ian Estepan, 617-274-4052
[email protected]
or
W2O Group
Brian Reid, 212-257-6725
[email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 3.94
SRPT's PB Ratio is ranked lower than
61% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. SRPT: 3.94 )
Ranked among companies with meaningful PB Ratio only.
SRPT' s PB Ratio Range Over the Past 10 Years
Min: 2  Med: 5.22 Max: 238.78
Current: 3.94
2
238.78
PS Ratio 78.93
SRPT's PS Ratio is ranked lower than
92% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. SRPT: 78.93 )
Ranked among companies with meaningful PS Ratio only.
SRPT' s PS Ratio Range Over the Past 10 Years
Min: 1.56  Med: 24.92 Max: 39930
Current: 78.93
1.56
39930
EV-to-EBIT -5.35
SRPT's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. SRPT: -5.35 )
Ranked among companies with meaningful EV-to-EBIT only.
SRPT' s EV-to-EBIT Range Over the Past 10 Years
Min: -29.1  Med: -5.3 Max: -0.8
Current: -5.35
-29.1
-0.8
EV-to-EBITDA -5.49
SRPT's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. SRPT: -5.49 )
Ranked among companies with meaningful EV-to-EBITDA only.
SRPT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -30.4  Med: -5.5 Max: -0.9
Current: -5.49
-30.4
-0.9
Current Ratio 6.13
SRPT's Current Ratio is ranked higher than
57% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. SRPT: 6.13 )
Ranked among companies with meaningful Current Ratio only.
SRPT' s Current Ratio Range Over the Past 10 Years
Min: 0.76  Med: 6.7 Max: 36.25
Current: 6.13
0.76
36.25
Quick Ratio 5.72
SRPT's Quick Ratio is ranked higher than
57% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. SRPT: 5.72 )
Ranked among companies with meaningful Quick Ratio only.
SRPT' s Quick Ratio Range Over the Past 10 Years
Min: 0.76  Med: 6.65 Max: 36.25
Current: 5.72
0.76
36.25
Days Inventory 13.00
SRPT's Days Inventory is ranked higher than
92% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. SRPT: 13.00 )
Ranked among companies with meaningful Days Inventory only.
SRPT' s Days Inventory Range Over the Past 10 Years
Min: 13  Med: 17987.48 Max: 17987.48
Current: 13
13
17987.48
Days Sales Outstanding 190.34
SRPT's Days Sales Outstanding is ranked lower than
94% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. SRPT: 190.34 )
Ranked among companies with meaningful Days Sales Outstanding only.
SRPT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 28.22  Med: 87.87 Max: 1158.5
Current: 190.34
28.22
1158.5
Days Payable 39.00
SRPT's Days Payable is ranked higher than
61% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. SRPT: 39.00 )
Ranked among companies with meaningful Days Payable only.
SRPT' s Days Payable Range Over the Past 10 Years
Min: 39  Med: 83360.38 Max: 83360.38
Current: 39
39
83360.38

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -13.20
SRPT's 3-Year Average Share Buyback Ratio is ranked lower than
57% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. SRPT: -13.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SRPT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -27.6  Med: -20.4 Max: -11.6
Current: -13.2
-27.6
-11.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 5.52
SRPT's Price-to-Net-Cash is ranked lower than
53% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. SRPT: 5.52 )
Ranked among companies with meaningful Price-to-Net-Cash only.
SRPT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.03  Med: 6.52 Max: 72.6
Current: 5.52
3.03
72.6
Price-to-Net-Current-Asset-Value 4.53
SRPT's Price-to-Net-Current-Asset-Value is ranked higher than
54% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. SRPT: 4.53 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SRPT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.95  Med: 6.24 Max: 42
Current: 4.53
2.95
42
Price-to-Tangible-Book 4.02
SRPT's Price-to-Tangible-Book is ranked lower than
54% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. SRPT: 4.02 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SRPT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.41  Med: 4.88 Max: 395
Current: 4.02
2.41
395
Price-to-Median-PS-Value 3.17
SRPT's Price-to-Median-PS-Value is ranked lower than
97% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. SRPT: 3.17 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SRPT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.08  Med: 4.05 Max: 1605.5
Current: 3.17
0.08
1605.5
Earnings Yield (Greenblatt) % -18.64
SRPT's Earnings Yield (Greenblatt) % is ranked lower than
75% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. SRPT: -18.64 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SRPT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -65.93  Med: 0 Max: 82
Current: -18.64
-65.93
82

More Statistics

Revenue (TTM) (Mil) $21.76
EPS (TTM) $ -2.69
Beta2.08
Short Percentage of Float23.08%
52-Week Range $14.83 - 63.73
Shares Outstanding (Mil)54.96
» More Articles for SRPT

Headlines

Articles On GuruFocus.com
Perceptive and Edelmen's Next NASDAQ IPO Debutant May 04 2017 
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 01 2017 
Sarepta Therapeutics Announces First Quarter 2017 Financial Results and Recent Corporate Development Apr 27 2017 
Scott+Scott, Attorneys at Law, LLP Reminds Investors of its Investigation of Sarepta Therapeutics, I Apr 18 2017 
Sarepta Therapeutics to Announce First Quarter 2017 Financial Results and Recent Corporate Developme Apr 17 2017 
Sarepta Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Apr 05 2017 
Sarepta Therapeutics Announces Appointment of Catherine Stehman-Breen, M.D., M.S. as Chief Medical O Apr 03 2017 
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Mar 31 2017 
Sarepta Therapeutics Announces Addition of Kenneth Fischbeck, M.D. and Matthew Wood M.D., Ph.D. to t Mar 30 2017 
Sarepta Therapeutics Announces Presentations at the 2017 MDA Scientific Conference Mar 17 2017 

More From Other Websites
Sarepta's Most Famous Drugs and Medications May 24 2017
Why Zoe's Kitchen, GOL, and Sarepta Therapeutics Slumped Today May 22 2017
Top hedge fund managers shared these 5 trade ideas at the SALT Conference May 20 2017
SALT Spotlight: Why Sarepta is a Buy May 18 2017
Big Fund Managers Offer Up Stock Pick Ideas May 18 2017
Tourbillon's Karp says Sarepta shares could surge 200 pct May 18 2017
How the FDA Approved a $300,000-a-Year Drug Its Own Experts Didn't Believe Worked May 18 2017
​Former Sarepta CEO launches biotech accelerator with $25M backing May 18 2017
Henri Termeer, 'giant of biotech' and longtime CEO of Genzyme, dies at 71 May 14 2017
Should You Buy Into the Hype Surrounding These Stocks? May 06 2017
Sarepta Therapeutics Inc. Stock Rose 22.5% in April. Here's Why. May 06 2017
Edited Transcript of SRPT earnings conference call or presentation 27-Apr-17 8:30pm GMT May 03 2017
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 01 2017
How Much Would Sarepta Therapeutics Fetch in a Buyout? May 01 2017
Sarepta: Forget a Takeover. This is Why Its CEO's Departure Could Be Good News May 01 2017
Today's Research Reports on Trending Tickers: Sanofi and Sarepta Therapeutics May 01 2017
Sarepta Pops On Consensus-Topping Revenue, Boosts 2017 Guide Apr 28 2017
Sarepta Tests Biotech's CEO Vacuum Hypothesis Apr 28 2017
​Sarepta shares jump as CEO’s planned exit spurs takeover speculation Apr 28 2017
Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Pick Up Apr 28 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)